Compare AAUC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAUC | MLYS |
|---|---|---|
| Founded | N/A | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | 2023 | 2023 |
| Metric | AAUC | MLYS |
|---|---|---|
| Price | $21.23 | $24.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $48.67 |
| AVG Volume (30 Days) | 304.4K | ★ 1.2M |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $94.92 | N/A |
| Revenue Next Year | $27.93 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.60 | $22.30 |
| 52 Week High | $32.20 | $47.65 |
| Indicator | AAUC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 37.90 |
| Support Level | $20.55 | $22.36 |
| Resistance Level | $24.82 | $31.36 |
| Average True Range (ATR) | 0.72 | 1.44 |
| MACD | -0.14 | -0.45 |
| Stochastic Oscillator | 21.70 | 2.90 |
Allied Gold Corp is a company focused on gold mining activities in Africa. Allied has three mines and several development and exploration projects in Africa, where it has operating experience. Operations are located in Cote d'Ivoire, Mali, and Ethiopia. The company expands and optimizes initiatives at existing operating mines, develops new mines, advances its exploration properties, and targets other consolidation opportunities, with a focus on Africa.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.